Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young boys, due to pituitary gland disorders and other diseases, due to which the testicles of the young males does not drop down naturally into the scrotum.
The HCG is usually administered as an injection under the skin into a muscle. The HCG can also be administered at home under the advice of a gynecologist or a pharmacist. The HCG levels can be determined with the help of urine or blood test. Result of specific test helps in the determining accurate measurement of the levels. These tests are mostly used to identify and confirm pregnancy or as a screening test to determine birth defects.
According to Centers of Disease Control and Prevention (CDC) in 2016, approximately 7.3 million women aged 15 – 44 have used infertility services. Moreover, 6.7% of the married women aged 15 – 44 were reported infertile. According to Azura Vascular Care, around 17% of the couples in the U.S. deal with infertility out of which 30% cases are a result of male infertility. These numbers suggests significant demand for infertility treatments, such as HCG in order for females to conceive a child. According to a statistical survey conducted by HealthGrove, pituitary gland disorders resulted into the death of around 205 people in 2015, out of which highest percentage belonged to white men.
Request for the Customization Of the Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/1011
The key players operating the global human chorionic gonadotropin market include Merck & Co., Inc., EMD Sereno, Inc., Fresenius Kabi, Bristol Myers Squibb Company, Ferring BV, and Kamia Biomedical Company. Acris Antibodies developed a human chorionic gonadotropin hormone by recombinant DNA technology that helps to prevent the disintegration of the corpus luteum of the ovary thereby, maintaining levels of progesterone production for healthy pregnancy in females.
North America to dominate global human chorionic gonadotropin (HCG) market, owing to rising frequency of infertility cases
On the basis of geography, the global human chorionic gonadotropin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is the highest regional contributor to the market and is expected to continue as a regional dominator over the forecast years. This primarily owes to the rising number of infertility cases as well as hormonal dysfunction among young males and females as a result of changing lifestyle. According to Mayo Clinic, around 25% of women fertility problems in the U.S. are a result of ovulation issues that are mostly caused due to dysfunction of human chorionic gonadotropin (HCG) hormone. Thus, the rapidly increasing cases of infertility are expected to surge the North America global human chorionic gonadotropin market.